Status of circulatory level of secreted frizzled related protein 4 in metabolic syndrome

Sushil Yadav; Vinod Kumar Singh; Pradeep Kumar; Preeti Sharma

doi:10.53730/ijhs.v6nS6.12161

Authors

Sushil Yadav Ph.D Scholar, Department of Biochemistry, Santosh Medical College, Ghaziabad, U.P, India
Vinod Kumar Singh Professor, Department of Medicine, TMMC & RC, Moradabad, U.P, India
Pradeep Kumar Professor, Department of Biochemistry, Autonomous State Medical College, Fatehpur, U.P, India
Preeti Sharma
prcdri2003@yahoo.co.in
Professor, Department of Biochemistry, Santosh Medical College, Ghaziabad, U.P, India

Keywords:

secreted frizzled related protein 4, metabolic syndrome, type II diabetes mellitus, adipocytokine

Abstract

Background: Metabolic syndrome is a set of metabolic disorders and is considered as a predictor of cardiovascular risks. The expression of several specific genes and the related protein products also show their significance in pathophysiology of Metabolic Syndrome. Secreted Frizzled Related Protein 4 is a product of expression of SFRP4 genes. SFRP4 has been linked with inflammatory responses quite similar to the responses as in metabolic syndrome pathogenesis. Aim: The current study aimed to assess the circulatory level of Secreted Frizzled Related Protein 4 among metabolic syndrome individuals. Method: Estimation of SFRP4 was done by ELISA technique by using Human SFRP4 ELISA kit (Make- Bioassay Technology Laboratory, Cat no- E2327Hu, Zeijhang, China). Results: Mean concentration of serum SFRP4 in Metabolic Syndrome subjects (2.06 ± 1.39 ng/ml) was significantly higher than the mean concentration of healthy controls (1.28 ± 1.29 ng/ml) (p< 0.05 ^*). Conclusion: A significant correlation of serum SFRP4 level with Fasting blood glucose and HbA1c seen in the findings of this study puts on an extra contribution to consider this protein as a potential Biomarker for Type II Diabetes Mellitus.

Downloads

Download data is not yet available.

References

Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, et al. Analysis of inflammatory mediators in type 2 diabetes patients. Int J Endocrinol. 2013; 976810.

Anand K, Vidyasagar S, Lasrado I, Pandey GK, Amutha A, Ranjani H, Anjana RM, et al. Secreted frizzled-related protein 4 (SFRP4): a novel biomarker of beta-cell dysfunction and insulin resistance in individuals with prediabetes and type 2 diabetes. Diabetes Care. 2016; 39: 147–8.

Bekaert M, Ouwens DM, Horbelt T, Velde FV, Fahlbusch P, Wiza DH, Nieuwenhove YV, et al. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity. Obesity. 2016; 24: 2544–52.

Bergmann K, Sypniewska G. Secreted frizzled-related protein 4 (SFRP4) and fractalkine (CX3CL1)—Potential new biomarkers for beta-cell dysfunction and diabetes. Clin Biochem. 2014; 47: 529–32.

Brix JM, Krzizek EC, Hoebaus C, Ludvik B, Schernthaner GH et al. Secreted Frizzled Related Protein 4 (SFRP4) is elevated in patients with Diabetes Mellitus. Horm Metab Res. 2016; 48(5):345-8.

Guan H, Zhang Y, Gao S, et al. Differential patterns of secreted frizzled-related protein 4 (SFRP4) in adipocyte differentiation: Adipose depot specificity. Cell Physiol Biochem. 2018; 46: 2149–64.

Hennekens C, Lieberman E, Rubenstein M, et al. Lipid Modification in the Treatment and Prevention of Cardiovascular Diseases: New emerging clinical and public health challenges. In: Watson RR, ed. Handbook of Cholesterol. Urbana, IL: AOCS Press. 2016; 155-81. Chap 9.

Hennekens CH, Andreotti F. The leading avoidable cause of premature mortality in the world: the case for obesity. Am J Med. 2013; 126(2):97-8. PMID: 23331432.

Hoffmann MM, Werner C, Bohm M, Laufs U, Winkler K. Association of secreted frizzled-related protein 4 (SFRP4) with type 2 diabetes in patients with stable coronary artery disease. Cardiovasc Diabetol. 2014; 13:155.

Mahdi T, Hanzelmann S, Salehi A, Muhammed SJ, Reinbothe TM, Tang Y, Axelsson AS, et al. Secreted frizzled-related protein 4 reduces insulin secretion and is overexpressed in type 2 diabetes. Cell Metab. 2012; 16: 625–33.

Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb. 2011; 18(8): 629–39.

Munro JM, Cotran RS. The pathogenesis of atherosclerosis: Atherogenesis and inflammation. Lab Invest. 1988; 58: 249–61.

Ouchi N, Higuchi A, Ohashi K, et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science. 2010; 329:454–57.

Reddy P, Lent-Schochet D, Ramakrishnan N, et al. Metabolic syndrome is an inflammatory disorder: A conspiracy between adipose tissue and phagocytes. Clin Chem Acta. 2019; 496: 35–44.

Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med. 1999; 340: 115–26.

Sherling DH, Perumareddi P, Hennekens CH. Metabolic Syndrome: Clinical and Policy Implications of the New Silent Killer. J. Cardiovasc. Pharmacol. 2017; 22(4): 365-7.

Trayhurn P, Drevon CA, Eckel J. Secreted proteins from adipose tissue and skeletal muscle—Adipokines, myokines and adipose/- muscle cross-talk. Arch Physiol Biochem. 2011; 117: 47–56.

Wardana, I. M., Ardani, I. G. A. I., Aryani, L. N. A., Windiani, I. G. A. T., Adnyana, I. G. N. S., & Setiawati, Y. (2022). Other mental disorders ydt due to brain damage and dysfunction and physical disease in patients with anti-NMDA encephalitis: Case report. International Journal of Health & Medical Sciences, 5(4). https://doi.org/10.21744/ijhms.v5n4.1948

Widana, I.K., Sumetri, N.W., Sutapa, I.K., Suryasa, W. (2021). Anthropometric measures for better cardiovascular and musculoskeletal health. Computer Applications in Engineering Education, 29(3), 550–561. https://doi.org/10.1002/cae.22202